Anti-Clever-1 Monoclonal Antibody Fp-1305
Chronic Myelomonocytic Leukemia
Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Faron Pharmaceuticals Ltd
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05428969CT.gov A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Clever-1 Monoclonal Antibody Fp-1305 (this asset) | Faron Pharmaceuticals Ltd | P1/2 | CC · 43 |
| Pevonedistat | Takeda | P3 | BB |
| Venetoclax | Servier Bio-Innovation LLC | P2/3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| Azacitidine | The University of Hong Kong | P3 | BB |
| Astx727 | Taiho Oncology, Inc. | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BB |
+42 more in the Chronic Myelomonocytic Leukemia cohort
Other indications for Anti-Clever-1 Monoclonal Antibody Fp-1305
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Carcinoma | — | P1/2 | CCC · 48 |
| Renal Cell Carcinoma | — | P1/2 | CC · 47 |
| Cancer | — | P1/2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Anti-Clever-1 Monoclonal Antibody Fp-1305 in Chronic Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/anti-clever-1-monoclonal-antibody-fp-1305-chronic-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →